WebDoctor Encyclopedia

Childhood Soft-tissue sarcomas

Alveolar rhabdomyosarcoma

Alveolar rhabdomyosarcoma is a fast-growing soft-tissue cancer of older children, teenagers and young adults. Most cases carry a PAX3 or PAX7 fusion with FOXO1, which guides treatment.

Medically reviewed Last reviewed October 17, 2026

What is alveolar rhabdomyosarcoma?

Alveolar rhabdomyosarcoma (ARMS) is a fast-growing cancer of the soft tissues. It belongs to the rhabdomyosarcoma family, the commonest group of soft-tissue cancers in children.

Rhabdomyosarcomas start from immature cells that would normally develop into skeletal (voluntary) muscle. Despite this, they can grow almost anywhere in the body, including places with little muscle, such as the nose or the bladder.

The word “alveolar” describes how the cells look under the microscope. They form small clusters separated by thin walls, a pattern that resembles the tiny air sacs (alveoli) of the lung. The cancer has nothing to do with the lungs.

ARMS mainly affects older children, teenagers and young adults. It most often starts in the arms, legs, trunk or the area around the anus and genitals.

Most cases carry a typical gene change, a fusion between the PAX3 or PAX7 gene and the FOXO1 gene. Doctors now use this fusion, rather than the microscope pattern alone, to decide how intensive treatment needs to be.

ARMS is treated with a combination of chemotherapy, surgery and radiotherapy. Many young people with localised disease are cured, but the outlook is harder when the cancer has spread.

1. Key facts at a glance

Feature Details
Type of cancer Soft-tissue sarcoma; a subtype of rhabdomyosarcoma
How common About 20-30% of all rhabdomyosarcomas; rhabdomyosarcoma as a whole affects about 4-5 children per million each year
Typical age Any age, but mostly 10-25 years; also seen in infants and adults
Sex Boys and girls are affected about equally
Main sites Arms and legs (including hands and feet), trunk, perineum and perianal area, paraspinal area, head and neck
Key gene change PAX3::FOXO1 or PAX7::FOXO1 fusion in about 80%
Spread Lymph nodes, bone marrow, bones and lungs
Main treatments Multi-drug chemotherapy, surgery, radiotherapy, maintenance chemotherapy
Outlook Roughly 50-65% long-term survival for localised disease; much lower when it has spread at diagnosis

The World Health Organization (WHO) recognises four main types of rhabdomyosarcoma. ARMS is the second most common after the embryonal type.

Type Who it affects Typical features
Embryonal Mostly children under 10 Commonest type; head and neck, bladder, prostate; usually no gene fusion
Alveolar Older children, teenagers, young adults Limbs, trunk, perineum; PAX::FOXO1 fusion in most; more likely to spread
Spindle cell / sclerosing Infants and adults Some carry MYOD1 mutations or VGLL2/NCOA2 fusions
Pleomorphic Older adults Large, very abnormal cells; usually in the thigh

Within ARMS, doctors distinguish two groups by genetic testing:

Group Share of ARMS What it means
Fusion-positive, PAX3::FOXO1 About 60% The most aggressive form, especially when it has spread
Fusion-positive, PAX7::FOXO1 About 20% Often in younger patients; somewhat better outlook than PAX3
Fusion-negative About 20% Behaves much like embryonal rhabdomyosarcoma and is treated like it

3. Causes and risk factors

In almost everyone with ARMS, there is no known cause. It is not caused by injury, diet or anything a parent did or did not do.

The cancer develops when two chromosomes break and rejoin in the wrong way inside a single cell. This joins part of the PAX3 (chromosome 2) or PAX7 (chromosome 1) gene to the FOXO1 gene on chromosome 13.

The new fusion protein switches on genes that keep the cell in an immature, rapidly dividing state. It also helps the cells move and spread.

Factor Notes
Acquired gene fusion Found only in the tumour, not in the rest of the body, and not passed on to children
Inherited syndromes Li-Fraumeni syndrome, neurofibromatosis type 1, Costello and Noonan syndromes and DICER1 syndrome raise the risk of rhabdomyosarcoma, mainly the embryonal type
Family history Most families have no history of cancer; genetic counselling is offered if there are other cancers in the family
Environment No clear environmental cause has been proven

4. How does it look?

4.1 On the body

Feature What it looks or feels like
Lump A firm, deep swelling in the arm, leg, hand, foot, buttock or trunk, often painless at first
Growth Gets bigger over weeks rather than months
Skin Usually normal over the lump; it may look stretched, shiny or bluish when the tumour is large
Perineum A lump near the anus, scrotum or vulva that may be mistaken for an abscess or hernia
Lymph nodes Firm, enlarged glands in the groin, armpit or neck
Face and eye Swelling of the cheek or eyelid, or an eye that bulges forward, when the tumour is in the head and neck

4.2 On scans

Test Typical findings
Ultrasound A solid mass with a good blood supply; often the first test for a new lump
MRI The best way to see the tumour and how far it reaches into muscle, bone, nerves and vessels; bright on T2 images and enhancing after contrast
CT of the chest Looks for small spots of spread in the lungs
PET-CT Shows active disease in lymph nodes, bone and bone marrow; helpful because ARMS often spreads to these areas

4.3 Under the microscope

Feature What the pathologist sees
Pattern Nests of small, round, blue cells separated by thin fibrous walls; the cells in the middle fall apart, leaving spaces like alveoli
Solid variant Sheets of cells without the alveolar spaces; still counted as ARMS
Muscle markers Strong staining for myogenin and desmin, and for MyoD1
Giant cells Large cells with several nuclei arranged in a ring may be present
Genetic test FISH, RT-PCR or sequencing shows the PAX3::FOXO1 or PAX7::FOXO1 fusion

5. Symptoms

The symptoms depend on where the tumour grows. Many children feel well at first, and the only sign is a lump that keeps growing.

5.1 Symptoms by site

Site Common symptoms
Arm, leg, hand or foot Growing lump, aching or pain, stiffness, limp or reduced use of the limb
Trunk or back Lump in the chest wall or back; back pain; weakness or numbness if the spine is pressed
Perineum or perianal area Lump, pain on sitting, constipation or problems passing urine
Head and neck Blocked nose, nosebleeds, ear discharge, facial swelling, double vision or a bulging eye
Lymph nodes Painless, firm swelling in the groin, armpit or neck

5.2 Symptoms of spread

Area Possible symptoms
Bone marrow Tiredness, pale skin, bruising and infections due to low blood counts
Bones Bone pain, sometimes at night, or a fracture after minor injury
Lungs Cough or breathlessness, though lung spots often cause no symptoms
General Weight loss, fever or feeling generally unwell

5.3 When to see a doctor

See a doctor if a lump:

  • Is larger than about 5 cm (the size of a golf ball)
  • Keeps growing over two to four weeks
  • Is deep in the muscle rather than just under the skin
  • Comes back after it has been removed
  • Is painful without an obvious injury

Most lumps in children are harmless, but a deep, growing lump needs an urgent scan and, if needed, a biopsy at a specialist sarcoma or children’s cancer centre.

6. Diagnosis

A biopsy is the only way to confirm ARMS. It should be planned by the team who will treat the child, so that the biopsy track can be removed later if surgery is needed.

Test Why it is done
Core needle or open biopsy Confirms the diagnosis and provides tissue for genetic tests
Fusion testing (FISH, RT-PCR or sequencing) Shows whether the tumour is PAX3- or PAX7-fusion-positive, which guides risk group and treatment
MRI of the primary site Shows tumour size and its relation to nearby structures
CT chest Looks for lung spread
PET-CT or bone scan Looks for spread to lymph nodes and bone
Bone marrow aspirate and biopsy Checks for marrow involvement, which is relatively common in ARMS
Lymph node sampling Recommended for tumours of the arms and legs, where node spread is common even when nodes look normal
Blood tests Blood count, kidney and liver function before chemotherapy
Heart and hearing tests Baseline before drugs that can affect the heart or kidneys

7. Staging and risk groups

Doctors combine several pieces of information to place each patient in a risk group. This decides the intensity and length of treatment.

Factor What is assessed
Fusion status Fusion-positive tumours need more intensive treatment than fusion-negative ones
Site Favourable sites include the orbit, non-parameningeal head and neck and some genitourinary sites; limbs and trunk are unfavourable
Size Tumours over 5 cm carry a higher risk
Lymph nodes Node involvement raises the risk group
Surgery result Whether the tumour was completely removed before chemotherapy (IRS clinical group)
Distant spread Spread to lungs, bone, marrow or distant nodes means high-risk or very-high-risk disease
Age Children under 1 year and adults tend to do less well

Most patients with fusion-positive ARMS fall into the intermediate-risk or high-risk groups.

8. Treatment

Treatment is given at a specialist children’s or sarcoma centre, often as part of a clinical trial. It usually lasts about 9-12 months and combines three approaches.

8.1 Chemotherapy

Phase What it involves
Induction Several drugs given in cycles every three weeks. In North America the backbone is VAC (vincristine, actinomycin D, cyclophosphamide); in Europe it is IVA (ifosfamide, vincristine, actinomycin D), sometimes with doxorubicin
Local treatment Surgery and/or radiotherapy, usually after about 9-12 weeks of chemotherapy
Further cycles Chemotherapy continues after local treatment
Maintenance Six months of low-dose oral cyclophosphamide with weekly intravenous vinorelbine improved survival in high-risk rhabdomyosarcoma in the European RMS 2005 trial

8.2 Surgery and radiotherapy

Treatment When it is used Notes
Surgery When the tumour can be removed completely without serious loss of function Removal of affected lymph nodes may be added
Radiotherapy For almost all fusion-positive tumours, and when surgery would leave tumour behind or cause disability Typical doses are about 41-50 Gy; proton therapy may be used to spare growing tissues
Treatment of metastases Radiotherapy to sites of spread where possible Part of the plan for high-risk disease

8.3 If the cancer comes back

Option Notes
Second-line chemotherapy Combinations such as vincristine with irinotecan and temozolomide, or ifosfamide-based regimens
Further surgery or radiotherapy For a single site of relapse
Clinical trials New drugs, immunotherapy and targeted treatments are being tested

9. Side effects and late effects

Treatment is intensive, and side effects are expected. The team gives medicines to prevent sickness and treats infections quickly.

Effect Cause What helps
Low blood counts and infections Chemotherapy Blood tests, prompt antibiotics for fever, transfusions
Nerve tingling, constipation Vincristine Laxatives, dose adjustment
Bladder irritation Cyclophosphamide and ifosfamide Fluids and the protective drug mesna
Kidney problems Ifosfamide Regular kidney tests
Liver problems Actinomycin D Liver tests; rarely a serious liver condition (veno-occlusive disease)
Fertility Alkylating drugs and pelvic radiotherapy Sperm or egg/ovarian tissue storage before treatment where possible
Growth and bone changes Radiotherapy to growing tissues Physiotherapy, orthopaedic follow-up
Second cancers Chemotherapy and radiotherapy Lifelong follow-up

10. Outlook

The outlook depends mainly on whether the cancer has spread, the fusion status and the site.

Situation Approximate long-term survival
Localised, fusion-negative Similar to embryonal rhabdomyosarcoma; most are cured
Localised, fusion-positive About 50-65%
Metastatic, fusion-negative About 40-50%
Metastatic, fusion-positive Under 20-30%; poorest when there are several sites of spread or bone marrow involvement
Relapsed disease Often difficult to cure, especially after intensive first treatment

Numbers come from large groups of patients treated in the past. They cannot predict what will happen to any one person, and results continue to improve with new trials.

11. Follow-up and living with ARMS

After treatment, children and young adults have regular check-ups with scans for several years. Visits become less frequent with time.

Time after treatment Typical follow-up
Years 1-2 Clinic visit and scans of the original site and chest every 3-4 months
Years 3-5 Visits every 4-6 months
After 5 years Yearly review in a long-term follow-up clinic, with checks on growth, heart, kidneys, hearing, hormones and fertility

Practical support matters too. Teenagers and young adults may benefit from specialist teenage and young adult (TYA) services, help with school or work, and psychological support for the whole family.

12. Frequently asked questions

Question Answer
Is alveolar rhabdomyosarcoma inherited? Usually not. The gene fusion arises only in the tumour cells
Why is the fusion test so important? Fusion-positive tumours behave more aggressively and need more intensive treatment, while fusion-negative ones are treated like embryonal rhabdomyosarcoma
Can adults get it? Yes. Adults are treated with the same type of regimens, ideally at a sarcoma centre with links to children’s oncology
Will my child lose their hair? Most chemotherapy for ARMS causes temporary hair loss; hair grows back after treatment
Can my child go to school? Often yes, between treatments, when blood counts are safe; the team will advise

Resources

  1. WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
  2. Skapek, S.X. et al. (2019) ‘Rhabdomyosarcoma’, Nature Reviews Disease Primers, 5(1), p. 1.
  3. Sorensen, P.H. et al. (2002) ‘PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children’s Oncology Group’, Journal of Clinical Oncology, 20(11), pp. 2672-2679.
  4. Missiaglia, E. et al. (2012) ‘PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification’, Journal of Clinical Oncology, 30(14), pp. 1670-1677.
  5. Skapek, S.X. et al. (2013) ‘PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children’s Oncology Group report’, Pediatric Blood & Cancer, 60(9), pp. 1411-1417.
  6. Sultan, I. et al. (2009) ‘Comparing adult and pediatric rhabdomyosarcoma in the Surveillance, Epidemiology and End Results program, 1973 to 2005: an analysis of 2,600 patients’, Journal of Clinical Oncology, 27(20), pp. 3391-3397.
  7. Hawkins, D.S. et al. (2018) ‘Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the Children’s Oncology Group’, Journal of Clinical Oncology, 36(27), pp. 2770-2777.
  8. Bisogno, G. et al. (2019) ‘Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial’, The Lancet Oncology, 20(11), pp. 1566-1575.
  9. National Cancer Institute (2026) Childhood Rhabdomyosarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.